Previous 10 | Next 10 |
Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...
The pharmaceutical market reached a total value of US$1.27 trillion in 2020, according to data from Statista , up significantly from US$887 billion in 2010. By 2025, that value is expected to increase even further to an estimated US$1.6 billion. Experienced and novice invest...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences: Handelsbanken Life Science Innovation Day 2021 (Virtual) Date: Wednesday, Aug. 25, 2021 Presentation time: 10 a.m. ET Morgan Stanley 19...
Horizon Therapeutics has now reached a growth point that is supportive of long-term success due to multiple eggs in the basket. The company has 11 FDA approved drugs and 10 phase 2 or 3 clinical trials underway, with revenue growth currently averaging 91% per year over the past 10 yea...
Image source: The Motley Fool. Horizon Therapeutics PLC (NASDAQ: HZNP) Q2 2021 Earnings Call Aug 4, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Horizon Therapeutics PLC (HZNP) Q2 2021 Earnings Call Transcript
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2021 Q2 earnings call. For further details see: Horizon Therapeutics Public Limited Company 2021 Q2 - Results - Earnings Call Presentation
Horizon Therapeutics Public Limited Company (HZNP) Q2 2021 Earnings Conference Call August 4, 2021 08:00 ET Company Participants Tina Ventura - Senior Vice President, Investor Relations Tim Walbert - Chairman, President and Chief Executive Officer Paul Hoelscher - Executive Vice President and...
Horizon Therapeutics (NASDAQ:HZNP) gains 8.5% premarket following upbeat Q2 results for period ended June 30, 2021. Net Sales for Q2 were $832.5M, an increase of 80% compared to prior year, and ahead of analyst expectation of $697.69M. Orphan net sales rose 97% driven by the strong ...
Horizon Therapeutics (NASDAQ:HZNP): Q2 Non-GAAP EPS of $1.62 beats by $0.75; GAAP EPS of $0.67 beats by $0.39. Revenue of $832.5M (+79.9% Y/Y) beats by $134.81M. Record TEPEZZA® Second-Quarter 2021 Net Sales of $453.3 Million Driven by Strong Demand and Relaunch Execution; Increasing Ful...
-- Record Second-Quarter 2021 Net Sales of $832.5 Million Increased 80 Percent; Second-Quarter 2021 GAAP Net Income of $158.1 Million; Adjusted EBITDA of $366.9 Million -- -- Record TEPEZZA® (teprotumumab-trbw) Second-Quarter 2021 Net Sales of $453.3 Million Driven by Str...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...